证券日报网讯2月25日，广誉远（600771）在互动平台回答投资者提问时表示，公司将坚定不移落实 1541发展框架，并坚持以"增长"为核心，全力提升经营质量，持续推动业绩改善。 ...

证券日报网讯2月25日，广誉远（600771）在互动平台回答投资者提问时表示，公司所有发货均为正常 排产交付，公司产能能够满足市场需求，渠道库存良性，产品供应稳定。公司将持续做好生产组织与供 应保障，确保产品供应稳定、顺畅。涉及公司具体经营数据，公司将按照相关规定及要求在定期报告中 进行披露。 ...

Group 1 - The recent policy benefits for the traditional Chinese medicine industry may positively impact Guangyuyuan (600771) [1] - The Ministry of Industry and Information Technology and seven other departments issued the "Implementation Plan for High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)" on February 12, 2026, outlining a five-year development blueprint [1] - The plan emphasizes the cultivation of high-standard raw material bases and promotes digital transformation, which aligns with Guangyuyuan's goals of brand protection and technological innovation [1] Group 2 - Guangyuyuan's stock price has shown a downward trend, closing at 17.73 yuan on February 13, 2026, down 1.99% from 18.23 yuan on February 9, 2026 [2] - The stock experienced a price fluctuation of 3.59% during this period, with a net outflow of 109.89 thousand yuan from institutional investors and a net inflow of 599.19 thousand yuan from retail investors on February 13, 2026 [2] - The technical analysis indicates that the stock is facing resistance at the 20-day pressure level of 18.44 yuan, with support around 17.58 yuan, and there are no significant reversal signals from indicators like MACD [2]

Group 1 - The company confirmed that all of its products are being produced and delivered normally, indicating stable production operations [2] - The company's production capacity is fully capable of meeting market demand, ensuring a reliable supply of products [2] - The company will continue to focus on production organization and supply assurance to maintain stable market supply [2]

Group 1 - The core viewpoint of the news is the release of the "Traditional Chinese Medicine Industry High-Quality Development Implementation Plan (2026-2030)" by the Ministry of Industry and Information Technology and seven other departments, which outlines a five-year development blueprint for the TCM industry, including the establishment of 60 high-standard TCM raw material production bases and the construction of five TCM industrial innovation centers by 2030 [1][2] - The implementation plan emphasizes the need for a collaborative development system across the entire TCM industry chain, enhancing the stable supply of key TCM raw materials, and achieving breakthroughs in critical technologies [2][6] - The plan includes six key focus areas for promoting high-quality development in the TCM industry, such as improving raw material quality and supply, collaborative innovation, manufacturing capacity enhancement, revitalizing the national medicine industry, promoting famous TCM products, and cultivating outstanding enterprises [2][4] Group 2 - Leading companies like Guangzhou Pharmaceutical Group are already implementing the policy by establishing standardized TCM material planting bases in various regions, which helps drive local industry development [3][6] - The plan encourages diversification in the TCM industry by promoting the development of health products, natural cosmetics, and specialty daily chemicals, thereby broadening the industry's boundaries and solidifying its foundation [3][4] - The plan aims to protect intellectual property rights for traditional crafts and well-known brands, while also identifying and nurturing new TCM products with significant clinical value [4][5] Group 3 - The implementation plan outlines 15 tasks to enhance the digital and green transformation of TCM manufacturing and to expand the international market for TCM [6][7] - The focus on intelligent upgrades and international expansion is highlighted as a key strategy for many TCM listed companies, with an emphasis on collaborative and intelligent-driven industry upgrades [6][7] - The establishment of "smart factories" and "green factories" is expected to facilitate the transition from traditional manufacturing to scientific production, ensuring product quality and standardization [7]

Core Viewpoint - Guangyuyuan (600771) is enhancing its retail coverage through the integration of the Meitehao retail network by Shennong Technology Group, providing opportunities for product sales [1] Group 1: Strategic Partnerships - The collaboration with China Resources Group is a normal business operation with strategic partners, aiding in product promotion and brand strength enhancement [1] Group 2: Business Focus and Improvement - The company is focusing on its core business and is actively improving its fundamentals through channel optimization, brand enhancement, academic research strengthening, and standardized management [1] - Key performance indicators are continuously improving [1]

Core Viewpoint - Guangyuyuan stated that the company is conducting its production and operations legally and compliantly, with all work proceeding normally [2] Group 1 - The company is actively engaging with investors through an interactive platform [2] - Guangyuyuan reassured investors about the legality and compliance of its operations [2] - The company confirmed that all aspects of its business activities are functioning as expected [2]

Core Viewpoint - Guangyuyuan (600771) has appointed Wang Penghao as the new Vice President, highlighting his extensive experience in the pharmaceutical industry and management roles [1] Group 1: Appointment Details - Wang Penghao was born in May 1975 and holds a Bachelor's degree in Business Administration [1] - His previous positions include roles at Bayer, Pfizer, GlaxoSmithKline, Ningbo Longsheng Pharmaceutical, Yangtze River Pharmaceutical Group, and Harbin Pharmaceutical Group [1] - Wang has no affiliations with the company's board, senior management, actual controllers, or shareholders holding more than 5% of the stock [1] Group 2: Compliance and Ownership - In the past three years, Wang has not faced any penalties from the China Securities Regulatory Commission or other relevant authorities, nor has he been sanctioned by the Shanghai Stock Exchange [1] - He currently does not hold any shares in the company [1]

Core Viewpoint - Guangyuyuan emphasizes its commitment to transparency and fairness in the procurement of bulk medicinal materials, stating that all relevant information will be published on authoritative platforms like "Chinese Medicinal Materials Network" [2] Group 1 - The company has clarified that it has never disclosed procurement information for bulk medicinal materials on its official website [2] - Guangyuyuan asserts that it has not made any adjustments to the links on its website, denying any claims of "cutting off connections" or limited knowledge among a few individuals [2] - The company's procurement activities are conducted in strict accordance with established bidding and procurement regulations, ensuring compliance with legal disclosure requirements [2]

Core Viewpoint - Guangyuyuan (600771) emphasizes that its product, Gui Ling Ji, is a prescription drug under the National Medicine Standard and should be used under professional medical guidance [1] Group 1: Product Information - Gui Ling Ji is indicated for "strengthening the body and brain, tonifying the kidney and qi, and enhancing appetite" [1] - The product is based on traditional Chinese medicine theory, which associates nasal inflammation with qi deficiency, suggesting that Gui Ling Ji may improve this condition by tonifying kidney qi to enhance lung qi [1] Group 2: Usage Recommendations - The company advises consulting a professional physician for personalized medication plans based on individual health conditions and historical usage records of Gui Ling Ji [1] - It is recommended to consider seasonal characteristics when formulating a personalized medication strategy to ensure safe and effective use [1]